Get the Stockscreener App
3.06
1.64%
0.01
Adagene Inc Adr stock is traded at $3.06, with a volume of 12,390.
It is up +1.64% in the last 24 hours and up +40.27% over the past month.
Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.
See More
Previous Close:
$3.05
Open:
$3.04
24h Volume:
12,390
Relative Volume:
0.15
Market Cap:
$135.68M
Revenue:
$18.11M
Net Income/Loss:
$-18.95M
P/E Ratio:
-3.5478
EPS:
-0.8625
Net Cash Flow:
-
1W Performance:
+0.00%
1M Performance:
+40.27%
6M Performance:
+28.63%
1Y Performance:
+129.63%
1-Day Range:
$2.93
$3.11
1-Week Range:
$2.60
$3.15
52-Week Range:
$1.31
$4.38
Adagene Inc Adr Stock (ADAG) Company Profile
Adagene Inc Adr Stock (ADAG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-25-21 | Initiated | China Renaissance | Buy |
| Mar-08-21 | Initiated | Goldman | Buy |
| Mar-08-21 | Initiated | Jefferies | Buy |
| Mar-08-21 | Initiated | Morgan Stanley | Overweight |
Adagene Inc Adr Stock (ADAG) Latest News
Short Interest in Adagene Inc. (NASDAQ:ADAG) Declines By 30.7% - MarketBeat
Adagene Inc. (NASDAQ:ADAG) Short Interest Update - MarketBeat
Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - The Manila Times
Adagene Announces Upcoming Poster Presentations on Masked - GlobeNewswire
Is DaVita (DVA) Stock Outpacing Its Medical Peers This Year? - MSN
HC Wainwright Analysts Lift Earnings Estimates for Adagene Inc. (NASDAQ:ADAG) - MarketBeat
Adagene Inc. to Post FY2024 Earnings of ($0.78) Per Share, HC Wainwright Forecasts (NASDAQ:ADAG) - Defense World
Adagene stock holds Buy rating as ESMO data reinforces drug potential in MSS-CRC - Investing.com
Adagene (NASDAQ:ADAG) Receives Buy Rating from HC Wainwright - Defense World
Adagene stock holds Buy rating as ESMO data reinforces drug potential in MSS-CRC By Investing.com - Investing.com South Africa
HC Wainwright Reiterates "Buy" Rating for Adagene (NASDAQ:ADAG) - MarketBeat
Adagene reports promising cancer therapy results - Investing.com
Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorect - StockTitan
Are Medical Stocks Lagging Adagene (ADAG) This Year? - Yahoo Finance
Adagene to Participate in Investor Conferences in September - GlobeNewswire
Adagene to Participate in Investor Conferences in September, Business Wires News - AsiaOne
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year? - MSN
Adagene Inc. (NASDAQ:ADAG) Short Interest Up 170.8% in August - Defense World
Liquidia (NASDAQ:LQDA) vs. Adagene (NASDAQ:ADAG) Critical Contrast - Defense World
Adagene Inc. (NASDAQ:ADAG) Short Interest Down 34.2% in July - MarketBeat
Is MannKind (MNKD) Stock Outpacing Its Medical Peers This Year? - MSN
Short Interest in Adagene Inc. (NASDAQ:ADAG) Decreases By 62.9% - Defense World
Adagene Reports Six Month Financial Results for 2024 and Provides Corporate Update - GlobeNewswire
Head-To-Head Survey: Altimmune (NASDAQ:ALT) vs. Adagene (NASDAQ:ADAG) - Defense World
Adagene (NASDAQ:ADAG) Rating Reiterated by HC Wainwright - MarketBeat
Adagene Inc. (NASDAQ:ADAG) Short Interest Up 45.9% in June - Defense World
Adagene Announces Poster Presentation on Masked Anti-CTLA-4 - GlobeNewswire
Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congress in September - Yahoo Finance
Adagene To Participate In The SVB Leerink 11th Annual Global Healthcare Conference - Barchart
Spruce Biosciences (NASDAQ:SPRB) and Adagene (NASDAQ:ADAG) Financial Contrast - Defense World
Adagene Reports Full Year 2021 Financial Results and Provides Corporate Update - Quantisnow
Adagene Announces Updates to its Board of Directors - Quantisnow
Adagene Announces Authorization of Share Repurchase Program up to US$10 Million - Quantisnow
Adagene Reports Full Year 2022 Financial Results and Provides Corporate Update - Quantisnow
Adagene to Participate in the SVB Leerink 11th Annual Global Healthcare Conference - Quantisnow
Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update - Quantisnow
Adagene Presents Data Demonstrating First and Best-in-Class Potential for Differentiated Preclinical Antibody Candidates at American Association for Cancer Research (AACR) Annual Meeting 2022 - Quantisnow
Adagene Announces SAFEbody® Multi-Target Collaboration with Sanofi for Novel Masked Immuno-Oncology Antibody ... - Quantisnow
Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugate - Quantisnow
Adagene (NASDAQ:ADAG) Given Buy Rating at HC Wainwright - Defense World
Adagene's (ADAG) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Adagene Inc. (NASDAQ:ADAG) Sees Large Increase in Short Interest - MarketBeat
Adagene Inc. (NASDAQ:ADAG) Short Interest Down 75.7% in May - MarketBeat
Adagene Inc. (NASDAQ:ADAG) Sees Large Drop in Short Interest - Defense World
Financial Analysis: Adagene Inc ADR (ADAG)'s Ratios Unveil Key Insights – DWinneX - The Dwinnex
Short Interest in Adagene Inc. (NASDAQ:ADAG) Decreases By 26.5% - MarketBeat
Adagene Inc. (NASDAQ:ADAG) Sees Significant Decrease in Short Interest - Defense World
Comparing Adagene (NASDAQ:ADAG) and Galera Therapeutics (NASDAQ:GRTX) - Defense World
Adagene to Present at Investor Conferences in June - GlobeNewswire
Short Interest in Adagene Inc. (NASDAQ:ADAG) Expands By 6.3% - MarketBeat
Adagene Inc Adr Stock (ADAG) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):